Do analysts rate EKF or TSTL?

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe EKF Diagnostics is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EKF or TSTL more profitable?

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets EKF Diagnostics 4.12% 3.01% 5.27% Tristel 15.88% 23.64% 9.89%

Do analysts prefer EKF or IUG?

EKF Diagnostics currently has a consensus price target of GBX 35, suggesting a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Intelligent Ultrasound Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Intelligent Ultrasound Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

EKF Diagnostics (EKF) Competitors

GBX 25 -0.30 (-1.19%)

As of 11:56 AM Eastern

Compare

EKF vs. NIOX, TSTL, SPEC, CREO, and IUG

Should you buy EKF Diagnostics stock or one of its competitors? EKF Diagnostics's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), INSPECS Group (SPEC), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does EKF Diagnostics compare to NIOX Group?

NIOX Group (LON:NIOX) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NIOX Group has higher earnings, but lower revenue than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.88	£995.88M	£1.64	41.46
EKF Diagnostics	£51.56M	2.08	£4.68M	£0.47	53.19

In the previous week, EKF Diagnostics had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for NIOX Group. NIOX Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
EKF Diagnostics	Neutral

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
EKF Diagnostics	4.12%	3.01%	5.27%

NIOX Group currently has a consensus price target of GBX 86, indicating a potential upside of 26.47%. EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

EKF Diagnostics beats NIOX Group on 7 of the 13 factors compared between the two stocks.

How does EKF Diagnostics compare to Tristel?

EKF Diagnostics (LON:EKF) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Tristel has lower revenue, but higher earnings than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.08	£4.68M	£0.47	53.19
Tristel	£49.54M	4.02	£6.54M	£16.24	25.55

EKF Diagnostics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Tristel has a beta of 0.346, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Tristel. EKF Diagnostics' average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Tristel	Neutral

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 22.5% of Tristel shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe EKF Diagnostics is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
Tristel	15.88%	23.64%	9.89%

Summary

EKF Diagnostics beats Tristel on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to INSPECS Group?

EKF Diagnostics (LON:EKF) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

EKF Diagnostics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market.

EKF Diagnostics presently has a consensus price target of GBX 35, indicating a potential upside of 40.00%. INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 37.82%. Given EKF Diagnostics' higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, EKF Diagnostics had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for INSPECS Group. EKF Diagnostics' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
INSPECS Group	Neutral

EKF Diagnostics has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.08	£4.68M	£0.47	53.19
INSPECS Group	£191.70M	0.55	-£4.11M	-£9.40	N/A

EKF Diagnostics has a net margin of 4.12% compared to INSPECS Group's net margin of -2.67%. EKF Diagnostics' return on equity of 3.01% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
INSPECS Group	-2.67%	-6.07%	0.45%

Summary

EKF Diagnostics beats INSPECS Group on 11 of the 13 factors compared between the two stocks.

How does EKF Diagnostics compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company	Overall Sentiment
Creo Medical Group	Neutral
EKF Diagnostics	Neutral

Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Creo Medical Group currently has a consensus target price of GBX 40, indicating a potential upside of 212.50%. EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Given Creo Medical Group's higher probable upside, equities research analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creo Medical Group	£6M	10.36	-£25.04M	£1.00	12.80
EKF Diagnostics	£51.56M	2.08	£4.68M	£0.47	53.19

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creo Medical Group	88.33%	9.56%	-20.09%
EKF Diagnostics	4.12%	3.01%	5.27%

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 7.0% of Creo Medical Group shares are owned by insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

EKF Diagnostics beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

EKF Diagnostics (LON:EKF) and Intelligent Ultrasound Group (LON:IUG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

EKF Diagnostics currently has a consensus price target of GBX 35, suggesting a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Intelligent Ultrasound Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Intelligent Ultrasound Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, EKF Diagnostics had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Intelligent Ultrasound Group. EKF Diagnostics' average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Intelligent Ultrasound Group	Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

EKF Diagnostics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

EKF Diagnostics has higher revenue and earnings than Intelligent Ultrasound Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.56M	2.08	£4.68M	£0.47	53.19
Intelligent Ultrasound Group	£6.57M	0.00	-£2.27M	-£0.68	N/A

EKF Diagnostics has a net margin of 4.12% compared to Intelligent Ultrasound Group's net margin of -23.11%. EKF Diagnostics' return on equity of 3.01% beat Intelligent Ultrasound Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.12%	3.01%	5.27%
Intelligent Ultrasound Group	-23.11%	-23.58%	-13.51%

Summary

EKF Diagnostics beats Intelligent Ultrasound Group on 13 of the 14 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EKF vs. The Competition

Export

Metric	EKF Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£107.49M	£5.82B	£7.15B	£2.90B
Dividend Yield	4.65%	1.75%	2.53%	6.17%
P/E Ratio	53.19	21.34	211.64	367.26
Price / Sales	2.08	70.53	618.40	83,668.69
Price / Cash	10.64	33.16	77.20	27.89
Price / Book	1.62	6.04	12.92	6.92
Net Income	£4.68M	£148.55M	£3.47B	£5.89B
7 Day Performance	1.21%	-1.69%	-0.84%	-0.15%
1 Month Performance	-3.18%	5.39%	7.15%	2.81%
1 Year Performance	-18.90%	5.27%	24.74%	21.71%

EKF Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
EKF EKF Diagnostics	1.93 of 5 stars	GBX 25 -1.2%	GBX 35 +40.0%	-13.4%	£107.49M	£51.56M	53.19	356
NIOX NIOX Group	N/A	GBX 68 flat	GBX 86 +26.5%	-10.5%	£286.19M	£48.70M	41.46	92
TSTL Tristel	N/A	GBX 428.75 +0.3%	N/A	+15.9%	£205.79M	£49.54M	26.40	208
SPEC INSPECS Group	0.4756 of 5 stars	GBX 100 +4.2%	GBX 60 -40.0%	+114.0%	£109.18M	£191.70M	N/A	1,673
CREO Creo Medical Group	N/A	GBX 13 +1.0%	GBX 40 +207.7%	+1.0%	£63.16M	£6M	13.00	279

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:EKF) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EKF Diagnostics (EKF) Competitors

EKF vs. NIOX, TSTL, SPEC, CREO, and IUG

How does EKF Diagnostics compare to NIOX Group?

Summary

How does EKF Diagnostics compare to Tristel?

Summary

How does EKF Diagnostics compare to INSPECS Group?

Summary

How does EKF Diagnostics compare to Creo Medical Group?

Summary

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKF vs. The Competition

EKF Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

EKF Diagnostics (EKF) Competitors

EKF vs. NIOX, TSTL, SPEC, CREO, and IUG

How does EKF Diagnostics compare to NIOX Group?

Which has more volatility and risk, NIOX or EKF?

Do institutionals and insiders believe in NIOX or EKF?

Which has preferable valuation & earnings, NIOX or EKF?

Does the media refer more to NIOX or EKF?

Is NIOX or EKF more profitable?

Do analysts rate NIOX or EKF?

Summary

How does EKF Diagnostics compare to Tristel?

Which has stronger earnings and valuation, EKF or TSTL?

Which has more volatility & risk, EKF or TSTL?

Does the media prefer EKF or TSTL?

Do institutionals & insiders believe in EKF or TSTL?

Do analysts rate EKF or TSTL?

Is EKF or TSTL more profitable?

Summary

How does EKF Diagnostics compare to INSPECS Group?

Do insiders & institutionals have more ownership in EKF or SPEC?

Which has more risk & volatility, EKF or SPEC?

Do analysts prefer EKF or SPEC?

Does the media favor EKF or SPEC?

Which has higher earnings and valuation, EKF or SPEC?

Is EKF or SPEC more profitable?

Summary

How does EKF Diagnostics compare to Creo Medical Group?

Does the media refer more to CREO or EKF?

Which has more volatility and risk, CREO or EKF?

Do analysts recommend CREO or EKF?

Which has stronger valuation & earnings, CREO or EKF?

Is CREO or EKF more profitable?

Do institutionals and insiders have more ownership in CREO or EKF?

Summary

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

Do analysts prefer EKF or IUG?

Does the media refer more to EKF or IUG?

Do institutionals & insiders hold more shares of EKF or IUG?

Which has more risk and volatility, EKF or IUG?

Which has higher valuation & earnings, EKF or IUG?

Is EKF or IUG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKF vs. The Competition

EKF Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools